Teva’s Focus On Its Core Means Increased Outlicensing Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s recent restricting has the firm focusing internal R&D on CNS and respiratory therapies, with plans to out-license or creatively finance development of non-core pipeline assets.